2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2378

Body Mass Index and Persistence of Conventional Dmards and TNF Inhibitors in Rheumatoid Arthritis
Abstract Number: 1636

Body Mass Index at Disease Onset Is Predictive of Future Organ Damage in Systemic Lupus Erythematosus
Abstract Number: 1472

Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry
Abstract Number: 609

Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Abstract Number: 1830

Bone Marrow Edema in Sacroiliac Joints of Young Athletes Is Common and Shows Most Frequently in the Posterior Lower Ilium
Abstract Number: 1224

BONE Metabolism in LIVER Transplant Patients Two-Year Study. Influence of Medical Intervention PRIOR to Surgery and Antiresorptive Treatment
Abstract Number: 1225

BONE Mineral Density and Vertebral Fractures in Gaucher Disease Patients Treated with Imiglucerase
Abstract Number: 22

Bone Regulatory Cytokine Production By B Cells in Rheumatoid Arthritis Is Dependent on NF-κb Activation and Autophagy Pathways
Abstract Number: 1183

Bone Sarcoidosis: A Multicenter Study
Abstract Number: 1594

Bone Turnover Markers in Adults with Systemic Lupus Erythematosus
Abstract Number: 2671

Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Abstract Number: 2319

Bradycardia after High-Dose Solu-Medrol
Abstract Number: 2753

Brain Functional Connectivity Features of Pain Centralisation Relate to Degree of ‘Fibromyalgianess’ in Rheumatoid Arthritis
Abstract Number: 1735

Brain Infiltrating CD4 T Cells Have a Pathogenic T Follicular Helper-like Phenotype in Neuropsychiatric Lupus
Abstract Number: 1912

Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].